Atossa Genetics to Announce First Quarter 2014 Financial Results and Provide a Company Update on Wednesday, May 14, 2014
Marketwire - Fri May 09, 3:16PM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will issue financial results and corporate developments for the First Quarter ended March 31, 2014, following the market close on Wednesday May, 14, 2014.
Atossa Genetics to Present at Sidoti & Company's Semi-Annual Microcap Conference
Marketwire - Fri May 02, 8:01AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Kyle Guse, CFO and General Counsel, will present at the Sidoti & Company Semi-Annual Microcap Conference on Friday, May 9 in New York City at the Grand Hyatt Hotel (109 E. 42nd St.) at 10:40 a.m.
Global & USA Cancer Biomarker Market Analysis 2014-2018
M2 - Thu May 01, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6wrk6/global_and_usa) has announced the addition of the "Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)" report to their offering. GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: 1.0 Executive Summary 2.0 Global Burden of Cancer 3.0 Oncogenic Biomarkers - An Overview 4.0 Biomarker Validation 5.0 Current and Prospective Oncogenic Biomarkers 6.0 Cancer Biomarker Test Market Analysis 2013-2018 7.0 Oncology Biomarker Market Main Industry Players 8.0 Oncology Biomarker Market Products and Kits 9.0 Market Participant Financial and Business Strategy Analysis 10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market Companies Mentioned - 23andMe - Affymetrix - Ambry Genetics - Astex Pharmaceuticals - Atossa Genetics - BioMerieux - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Foundation Medicine - Illumina - Genelex - Genomic Health - Myriad - Nodality - OriGene Technologies - Randox - Qiagen For more information visit http://www.researchandmarkets.com/research/j6...al_and_usa
Ben R. Chen Joins Atossa Genetics as Senior Vice President of Global Regulatory Affairs and Quality Assurance
Marketwire - Wed Apr 02, 7:31AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Ben R. Chen has joined the Company as Senior Vice President of Global Regulatory Affairs and Quality Assurance, a newly created position. Mr. Chen will oversee all facets of Atossa's regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities, and all quality assurance matters.
Atossa Genetics Announces 2013 Financial Results and Provides Company Update
Marketwire - Thu Mar 27, 3:02PM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced 2013 financial results and provided an update on recent corporate developments.
Atossa Genetics to Announce 2013 Financial Results and Provide a Company Update on Thursday, March 27, 2014
Marketwire - Mon Mar 24, 7:30AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it will issue financial results and corporate developments for the fiscal year ended December 31, 2013, following the close of market on Thursday, March 27, 2014.
Personalized Medicine and Companion Diagnostic Market Discussed in New Report by Kelly Scientific Publications Available at MarketPublishers.com
PRWeb - Fri Mar 07, 12:03PM CST
During the last 20 years, the ongoing genetic advances have considerably facilitated the emergence of personalized medicine sector as an important player in the overall healthcare universe. Human genome sequencing has propelled the pharmacogenetics sector. Furthermore, personalized medicine also takes into account pharmacogenomics studies, where protein and genetic interactions yield the potential drug targets. The key objective of personalized medicine is to offer individualized care that is more effective and specific to the potential patients. Targeted and personalized medicine R&D efforts are aimed at increasing the efficiency of the therapeutic area via genetic testing along with companion diagnostics. The introduction of novel personalized medicine will likely reduce the frequency of adverse drug reactions and thus have a significant influence on health economics. Diagnostic and developmental companies are predicted to take benefit from lower discovery and commercialization costs, as well as from more specific market sub-types awaited in the years ahead.
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Atossa Genetics to submit additional information to the US FDA for ForeCYTE Breast Aspirator
M2 - Wed Mar 05, 6:15AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) disclosed on Tuesday that the US Food and Drug Administration (FDA) has requested additional information related to the company's 510(k) application for the clearance of its ForeCYTE Breast Aspirator.
Atossa Genetics Inc. Announces FDA Response to 510(k) Submission for ForeCYTE Breast Aspirator
Marketwire - Tue Mar 04, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has received a request for additional information from the U.S. Food and Drug Administration (FDA) related to its 510(k) application for the ForeCYTE Breast Aspirator. Atossa plans to request an extension to the 30 day time limit by which a response must be provided to the FDA. If the request for an extension is granted, Atossa will have up to 180 days to provide a response to the FDA's questions. Atossa does not view the FDA's request for additional information as unusual or unexpected and will continue to work toward final clearance of the submission.
Atossa Genetics elects Richard I. Steinhart to board
M2 - Tue Mar 04, 5:10AM CST
Breast health company Atossa Genetics (NASDAQ:ATOS) revealed on Monday the addition of Richard I. Steinhart to its board of directors
Richard I. Steinhart Joins Atossa Genetics' Board of Directors
Marketwire - Mon Mar 03, 11:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS), announced today that Richard I. Steinhart has joined the Company's Board of Directors and has been appointed a Member of the Audit Committee and Compensation Committee.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BMO Economics: Business Investment and Housing to Lift Illinois' Economy 2.5 Percent in 2014
Marketwire - Tue Feb 04, 7:01AM CST
While economic growth in Illinois was challenged last year by a softening in factory activity and exports, 2014 will see the economy improve at a 2.5 percent pace, according to the bi-annual U.S. State Monitor Report from BMO Economics.
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Certain Officers and Directors of Atossa Genetics, Inc.
Business Wire - Fri Jan 31, 10:31AM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP today announced that it is investigating whether the board of directors of Atossa Genetics, Inc. (NASDAQ:ATOS) breached its fiduciary duties to shareholders related to Atossa's October 4, 2013 disclosure that it would be forced to recall its ForeCYTE Breast Health Test and Mammary Aspiration Specimen Cytology Test. The recall was necessary to address concerns raised by the U.S. Food and Drug Administration ("FDA"
Atossa Genetics Inc completes public offering of 5.834m units
M2 - Thu Jan 30, 3:30AM CST
Breast health company Atossa Genetics Inc (NASDAQ:ATOS) reported on Wednesday the completion of its public offering of 5,834,234 units.
Atossa Genetics Inc. Announces Closing of a Public Offering of Common Stock and Warrants
Marketwire - Wed Jan 29, 4:00PM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has closed a public offering of 5,834,234 units at a price to the public of $2.40 per unit. The Company has received approximately $14.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.
Real Good Solar Takes On New Name, Ticker Symbol and Strategy: Real Goods Solar Inc. (NASDAQ:RSOL), Atossa Genetics Inc. (NASDAQ: ATOS), Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP)
ACCESSWIRE - Tue Jan 28, 7:02AM CST
What makes a pioneering solar energy company change its name, ticker symbol and strategy after 36 years?
Atossa Genetics prices public offering at USD2.40 per unit
M2 - Mon Jan 27, 6:18AM CST
US-based breast health company Atossa Genetics Inc (NASDAQ:ATOS) said on Friday that it has priced its public offering of approximately 5.8m units.
Atossa Genetics Inc. Announces Pricing of a Public Offering of Common Stock and Warrants
Marketwire - Fri Jan 24, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has priced a public offering of approximately 5.8 million units at a price to the public of $2.40 per unit. The Company has received commitments and indications for approximately $14.0 million in gross proceeds. The sale of the units is expected to close on or about January 29, 2014, subject to the satisfaction of customary closing conditions. Each unit consists of one share of common stock and one warrant to purchase 0.20 of a share of common stock.